Rapport Therapeutics (RAPP) Consolidated Net Income (2023 - 2026)
Rapport Therapeutics (RAPP) reported Consolidated Net Income of -$19.9 million for Q1 2026, up 17.48% year-over-year from -$16.9 million in Q1 2025, and up 41.19% quarter-over-quarter from -$33.8 million in Q4 2025.
Rapport Therapeutics (RAPP) Consolidated Net Income (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has 4 years of Consolidated Net Income data on file, last reported at -$19.9 million in Q1 2026.
- Consolidated Net Income for Q1 2026 came in at -$19.9 million, up 17.48% year-over-year; the trailing twelve-month figure through Mar 2026 was -$107.3 million (down 34.6% YoY), and the FY2025 annual result was -$111.5 million, down 42.37% from the prior year.
- Consolidated Net Income grew to -$19.9 million in Q1 2026 per RAPP's latest filing, from -$33.8 million in the prior quarter.
- Over five years, Consolidated Net Income peaked at -$6.4 million in Q2 2023 and troughed at -$33.8 million in Q4 2025.
- A 4-year average of -$19.2 million and a median of -$19.0 million in 2024 frame the typical range for Consolidated Net Income.
- The sharpest annual moves came in 2024 and 2026: Consolidated Net Income slumped 182.65% in 2024, then gained 17.48% in 2026.
- A 4-year view of Consolidated Net Income shows it stood at -$13.5 million in 2023, then plunged by 47.79% to -$20.0 million in 2024, then slumped by 68.98% to -$33.8 million in 2025, then jumped by 41.19% to -$19.9 million in 2026.
- Business Quant data shows RAPP's Consolidated Net Income at -$19.9 million in Q1 2026, -$33.8 million in Q4 2025, and -$26.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -56.48 Mn |
| 10 | Rapport Therapeutics | 1.66 Bn | 1.66 Bn | - | -19.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.86 Mn |
| Dec 31, 2025 | -33.76 Mn |
| Sep 30, 2025 | -26.93 Mn |
| Jun 30, 2025 | -26.73 Mn |
| Mar 31, 2025 | -24.06 Mn |
| Dec 31, 2024 | -19.98 Mn |
| Sep 30, 2024 | -17.54 Mn |
| Jun 30, 2024 | -18.12 Mn |
| Mar 31, 2024 | -15.28 Mn |
| Dec 31, 2023 | -13.52 Mn |
| Sep 30, 2023 | -8.71 Mn |
| Jun 30, 2023 | -6.41 Mn |